By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

A pill that doubles life expectancy in patients with pancreatic cancer has been hailed as the biggest breakthrough for ...

Revolution Medicines’ RVMD Phase 3 daraxonrasib data in metastatic pancreatic cancer cut death risk 60% and doubled ...

Scientists at the world's largest cancer conference have hailed the start of a new drug 'revolution'.

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

A DAILY pill that can double pancreatic cancer survival time is the biggest breakthrough in decades, say doctors treating the ...

Please provide your email address to receive an email when new articles are posted on . Adding apalutamide to ADT before and ...

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...